Augmentin 250 mg/125 mg is a conventional immediate-release prescription antibiotic tablet containing 250 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. The two components have different functions: amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain beta-lactamase enzymes that can inactivate susceptible penicillin antibiotics. This is a specific two-ingredient tablet product, not plain amoxicillin 250 mg and not a general designation for every amoxicillin/clavulanate formulation containing 250 mg of amoxicillin.
The 250/125 mg tablet has a 2:1 amoxicillin-to-clavulanic-acid ratio. That ratio is central to recognizing the product because other formulations bearing a 250 mg amoxicillin designation may contain only 62.5 mg of clavulanic acid. In particular, the standard 250 mg/62.5 mg chewable tablet and the 250 mg/62.5 mg per 5 mL oral suspension are different products. The July 2026 FDA prescribing information explicitly states that the conventional 250/125 mg tablet is not interchangeable with the corresponding 250/62.5 mg chewable tablet and identifies no equivalent oral suspension or chewable strength in its formulation-switching table.
For U.S. prescription and pharmacy verification, the buyer's task is to identify the exact combination strength, dosage form, approved product and actual medicine being dispensed. A branded Augmentin tablet and an appropriately approved generic may have different packaging, manufacturers, labelers and physical markings. FDA approval records establish regulatory product information but do not guarantee current pharmacy inventory or suitability for a particular patient. This page focuses specifically on the 250/125 mg immediate-release tablet; the broader Augmentin tablets guide compares all three conventional tablet strengths.
The conventional Augmentin 250 mg/125 mg tablet is a fixed-combination oral antibiotic product containing amoxicillin and clavulanate potassium. Each tablet provides 250 mg of amoxicillin, supplied as amoxicillin trihydrate, and 125 mg of clavulanic acid, supplied as its potassium salt. These quantities identify one individual tablet rather than a daily dose, a treatment recommendation or the contents of an entire package.
The product belongs to the standard immediate-release Augmentin tablet family. Immediate-release describes the conventional formulation and distinguishes it from Augmentin XR, a separately labeled extended-release product. Although both contain amoxicillin and clavulanate, their pharmaceutical designs and ingredient proportions are different. A conventional 250/125 mg tablet should not be treated as a smaller interchangeable unit of an XR formulation.
The combination differs from plain amoxicillin because it contains an additional active component. Clavulanate can protect amoxicillin against certain beta-lactamase-mediated resistance mechanisms, but it does not overcome every form of bacterial resistance. The combination is not automatically preferable to amoxicillin alone, and its use depends on the infection, likely or confirmed organisms, susceptibility and other clinical considerations.
The proprietary Augmentin name refers to the branded product family. Generic products with corresponding active ingredients and strengths may be approved under separate FDA applications and marketed under established ingredient names. Product-specific approval and therapeutic-equivalence information determine the relevant regulatory relationship. The Augmentin brand guide explains the wider product family, while the generic amoxicillin/clavulanate guide covers the general combination-drug category.
This page deliberately concentrates on the 250/125 mg immediate-release tablet rather than selecting a medication strength, providing a treatment schedule or suggesting substitution between different products.
The expression 250 mg/125 mg represents two separate active-component quantities. The first number identifies 250 mg of amoxicillin, and the second identifies 125 mg of clavulanic acid supplied as clavulanate potassium. Both numbers must be retained when describing the tablet. A listing that displays only 250 mg may omit information needed to distinguish this combination from other medicines.
The tablet's amoxicillin-to-clavulanic-acid ratio is 2:1. This is a pharmaceutical composition ratio, not an indication of clinical strength, therapeutic superiority or recommended use. The same 250 mg amoxicillin amount can appear in other dosage forms with a different clavulanate quantity, producing a different combination product.
The distinction between the acid-equivalent amount and the potassium-salt form is also relevant to label interpretation. FDA labeling identifies the active ingredient as clavulanate potassium while expressing its strength in terms of clavulanic acid. The 125 mg quantity therefore describes the labeled clavulanic-acid equivalent rather than the total mass of the potassium salt.
The original branded 250/125 mg tablet and an appropriately approved generic of the same strength may differ in inactive ingredients, physical appearance and packaging. Those differences do not change how the two active-component strengths are expressed. However, matching the ingredient amounts alone is not sufficient to establish the therapeutic equivalence of unrelated dosage forms or release technologies.
For a prescription or pharmacy order, the relevant identity is the complete combination: amoxicillin 250 mg, clavulanic acid 125 mg, conventional oral tablet and the specific approved product being supplied.
| Product characteristic | FDA-labeled information | Why it matters |
|---|---|---|
| First active component | Amoxicillin 250 mg, supplied as amoxicillin trihydrate | Identifies the penicillin-class antibacterial component. |
| Second active component | Clavulanic acid 125 mg, supplied as clavulanate potassium | Identifies the beta-lactamase inhibitor component. |
| Ingredient proportion | 250:125, or 2:1 | Distinguishes the tablet from 250 mg/62.5 mg combination presentations. |
| Dosage form | Conventional immediate-release oral tablet | Distinguishes the product from chewable tablets, suspensions and XR. |
| Prescription status | Prescription-only antibacterial medicine | Requires appropriate clinical prescribing and lawful pharmacy dispensing. |
The FDA's July 2026 Augmentin prescribing information describes the branded 250 mg/125 mg tablet as a white, oval, film-coated tablet. The tablet is debossed with AUGMENTIN on one side and 250/125 on the other. These are specific identifying characteristics of the described branded presentation rather than universal appearance standards for all approved generic products.
The imprint 250/125 identifies the two-component strength pair on the original branded tablet. A patient should not confuse this marking with a standalone amoxicillin 250 mg product or a 250 mg/62.5 mg chewable tablet. The numerical similarity does not establish that the products contain the same quantity of clavulanic acid.
A genuine product-identification process should use more than tablet appearance. The actual pharmacy container label, proprietary or established drug name, dosage form, strength, manufacturer or labeler and applicable package identifiers provide important context. Product photographs may become outdated or represent different manufacturers, and a tablet's color or shape does not independently confirm regulatory approval.
Generic amoxicillin/clavulanate 250/125 mg tablets may have different imprints, shapes or inactive ingredients. Such differences can be consistent with an FDA-approved generic product, but the actual tablet must correspond to the approved product and the medicine documented by the dispensing pharmacy. Patients should ask a pharmacist to investigate any unexplained discrepancy before taking an uncertain tablet.
For a broader explanation of official packaging, labeler details and NDC verification, see the Augmentin product authenticity guide. This strength-specific page retains only the identification information needed to distinguish the 250/125 mg tablet.
One of the most important identification differences concerns the conventional 250 mg/125 mg tablet and the oral suspension containing 250 mg of amoxicillin and 62.5 mg of clavulanic acid per 5 mL after reconstitution. Both presentations contain a nominal 250 mg amoxicillin quantity in their stated unit, but the clavulanic-acid quantity differs substantially.
The 250/125 mg tablet contains 125 mg of clavulanic acid per tablet, producing a 2:1 ingredient ratio. By contrast, 5 mL of the 250/62.5 mg suspension contains 62.5 mg of clavulanic acid, producing a 4:1 ratio. The suspension is also a different dosage form, prepared from a powder before administration, with concentration-based labeling and product-specific storage instructions.
The FDA's July 2026 prescribing information provides a formulation-switching table that identifies no equivalent oral suspension or chewable-tablet strength for the conventional 250 mg/125 mg tablet. Accordingly, the 250/62.5 mg per 5 mL suspension should not be interpreted as a direct liquid equivalent of the 250/125 mg tablet. Similarity in amoxicillin content is insufficient to establish interchangeability.
Oral suspensions may be used in patient populations for whom tablets are not appropriate, but such decisions depend on the relevant indication, age, weight, swallowing ability and professional prescribing assessment. A liquid product is not automatically a suitable replacement for a tablet merely because its label contains the same first strength number.
The Augmentin oral suspension guide explains liquid concentrations, reconstitution and pharmacy product identification in more detail. The present page focuses on why the 250/125 mg conventional tablet must remain distinct from the 250/62.5 mg per 5 mL suspension.
| Identification feature | 250 mg/125 mg tablet | 250 mg/62.5 mg per 5 mL suspension |
|---|---|---|
| Dosage form | Conventional immediate-release oral tablet | Powder for oral suspension, reconstituted before administration |
| Amoxicillin amount | 250 mg per tablet | 250 mg per 5 mL of prepared suspension |
| Clavulanic acid amount | 125 mg per tablet | 62.5 mg per 5 mL of prepared suspension |
| Component ratio | 2:1 | 4:1 |
| FDA formulation-switching information | No equivalent suspension or chewable strength identified in Table 6 | Not a direct equivalent of the 250 mg/125 mg tablet |
| Product verification | Check tablet strength, dosage form, label and approved product identity | Check both concentration values, reconstitution status and pharmacy label |
The FDA specifically warns that the standard 250 mg/125 mg Augmentin tablet and the 250 mg/62.5 mg Augmentin chewable tablet are not interchangeable. Although each contains 250 mg of amoxicillin, the conventional tablet contains 125 mg of clavulanic acid while the chewable tablet contains 62.5 mg. They therefore have different active-component ratios.
The chewable presentation also belongs to a different dosage-form category. Its product characteristics, inactive ingredients and intended administration differ from those of the conventional film-coated tablet. FDA labeling specifies patient-population requirements for these formulations, including restrictions on the use of standard tablets in pediatric patients weighing less than 40 kg.
A search result or prescription summary that abbreviates both products as Augmentin 250 mg can conceal this meaningful difference. Accurate verification requires the full strength pair and dosage form. In particular, the label should distinguish a conventional tablet marked 250/125 from a chewable product containing 250/62.5 mg.
The FDA restriction is relevant to pharmacy fulfillment as well as medication safety. If the originally prescribed formulation cannot be supplied or administered appropriately, a healthcare professional must assess the available alternatives. Patients should not replace a conventional tablet with a chewable tablet independently.
The separate Augmentin chewable tablets guide covers chewable product strengths and identification characteristics. It does not change the non-equivalence of the 250/125 mg conventional tablet and the 250/62.5 mg chewable presentation.
The FDA prescribing information contains another explicit restriction involving the 250 mg/125 mg conventional tablet. Two tablets of this strength must not be substituted for one conventional 500 mg/125 mg Augmentin tablet. The reason is the difference in total clavulanic-acid content, even though the total amoxicillin amount would be the same.
Two 250/125 mg tablets contain a combined 500 mg of amoxicillin and 250 mg of clavulanic acid. One 500/125 mg tablet contains 500 mg of amoxicillin and only 125 mg of clavulanic acid. Doubling the number of 250/125 mg tablets therefore doubles the clavulanate amount relative to the single 500/125 mg tablet.
This comparison illustrates why the two-number strength designation is essential. Amoxicillin quantity alone is not enough to determine whether two combination products are equivalent. Clavulanate is an active component whose quantity must be accounted for when reviewing a prescription or proposed formulation change.
The FDA's formulation-switching guidance provides specific relationships for certain other conventional Augmentin strengths, but the 250/125 mg tablet has no equivalent oral suspension or chewable strength identified in Table 6. These distinctions are not instructions for choosing or adjusting doses. They are product-identification and professional dispensing considerations.
Readers comparing the broader tablet family can review the Augmentin tablet strength comparison. The individual Augmentin 500/125 mg guide covers that separate strength without implying that patients should switch between the two formulations.
| Comparison | Total amoxicillin | Total clavulanic acid | FDA labeling conclusion |
|---|---|---|---|
| One 250 mg/125 mg tablet | 250 mg | 125 mg | A distinct conventional tablet strength. |
| Two 250 mg/125 mg tablets | 500 mg | 250 mg | Not an acceptable direct substitute for one 500 mg/125 mg tablet. |
| One 500 mg/125 mg tablet | 500 mg | 125 mg | A different component ratio despite matching the two-tablet amoxicillin total. |
The Augmentin brand name identifies a proprietary product, while generic amoxicillin/clavulanate tablets are commonly labeled using the established ingredient names. An FDA-approved generic corresponding to the conventional 250 mg/125 mg tablet must meet applicable regulatory requirements for its specific approved product, including relevant pharmaceutical-equivalence and bioequivalence requirements.
The FDA Orange Book provides information about approved drug products, application numbers, dosage forms, strengths and applicable therapeutic-equivalence evaluations. A generic product approved through an Abbreviated New Drug Application, or ANDA, can have a different manufacturer or labeler and different tablet appearance from the branded reference product. Those differences should be evaluated using actual approval and product-label information rather than assumptions about the word generic.
A company name appearing in pharmacy information may identify an ANDA applicant, manufacturer, distributor or repackager. These are not necessarily the same entity. Likewise, an NDC associated with a generic package identifies a listed drug product or package but does not, by itself, establish current FDA approval status or product availability.
The term generic Augmentin is a useful consumer shorthand, but it must not obscure the exact dosage form and strength. A generic 250 mg/125 mg immediate-release tablet is a different product category from a generic 250 mg/62.5 mg chewable tablet or a 250 mg/62.5 mg per 5 mL suspension. Approved-product comparisons must preserve those distinctions.
The dedicated generic amoxicillin/clavulanate manufacturers directory addresses applicant, manufacturer and labeler identities. For regulatory approval and equivalence records, see the FDA-approved Augmentin products guide. This strength page intentionally avoids presenting an unverified directory of currently marketed manufacturers.
The practical verification task begins with a valid prescription for the intended antibiotic product. A licensed dispensing pharmacy must establish the prescribed strength, dosage form and applicable substitution requirements before supplying the medicine. A retail catalog listing or search result is not evidence that a specific branded or generic 250/125 mg tablet can currently be dispensed.
The product name should identify amoxicillin and clavulanate potassium, either under the Augmentin proprietary name or the appropriate generic established name. The complete strength should show 250 mg of amoxicillin and 125 mg of clavulanic acid. The dosage form should identify a conventional oral tablet, not a chewable tablet, oral suspension or extended-release product.
The pharmacy can also confirm the actual manufacturer or labeler, the NDC where applicable and the container-label information. These details help distinguish a dispensed product from a generic catalog entry, historical package record or similarly named medicine. Product packaging and approval records should be reconciled when the brand or generic identity matters.
If a prescription specifies the brand and an approved generic is being considered, the pharmacist must follow applicable prescription restrictions, therapeutic-equivalence information and state substitution requirements. The presence of the same two active ingredients does not authorize unrestricted substitution between different strength pairs or dosage forms.
Patients comparing online pharmacy services should verify appropriate prescription handling and relevant licensing information rather than relying on advertised availability. A pharmacy may display several products without having every package or manufacturer available for immediate dispensing. The Augmentin online pharmacy guide provides a broader framework for evaluating prescription-pharmacy services.
Any uncertainty about the dispensed formulation, directions or tablet appearance should be resolved directly with the dispensing pharmacist before use. This product-identification guide does not determine whether the medicine is clinically appropriate for an individual patient.
| Verification point | Information to confirm | Why it matters |
|---|---|---|
| Active ingredients | Amoxicillin and clavulanate potassium | Distinguishes the combination from plain amoxicillin. |
| Exact strength | 250 mg amoxicillin / 125 mg clavulanic acid | Prevents confusion with 250 mg/62.5 mg products. |
| Dosage form | Conventional immediate-release oral tablet | Separates the product from chewable, liquid and XR formulations. |
| Brand or generic | Actual product name and approved product identity | Determines what is being dispensed rather than merely advertised. |
| Manufacturer or labeler | Company identified for the supplied product | Supports identification of the specific marketed presentation. |
| NDC and package | Actual product and package identifiers where applicable | Supports verification but does not guarantee inventory or approval. |
| Prescription requirements | Valid prescription and applicable substitution restrictions | Ensures dispensing follows professional and legal requirements. |
The 250 mg/125 mg tablet is one member of the standard immediate-release tablet family. The conventional 500 mg/125 mg and 875 mg/125 mg tablets contain larger amoxicillin quantities while retaining 125 mg of clavulanic acid per tablet. The different component ratios matter for product identity and professional prescribing decisions. They should not be viewed as interchangeable variations of a single universal dose.
The Augmentin 875/125 mg tablet guide covers the highest-amoxicillin-strength conventional tablet presentation. A plain amoxicillin tablet with a similar amoxicillin amount remains a different medicine because it lacks clavulanate.
Augmentin XR is an extended-release tablet containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. Its release profile and labeled uses differ from those of standard immediate-release tablets. The Augmentin XR guide addresses that product separately. XR should not be treated as interchangeable with conventional tablets by comparing nominal amoxicillin totals.
Augmentin ES-600 is a distinct oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It has separate pediatric labeling and a different component proportion from the conventional 250/125 mg tablet. The Augmentin ES-600 guide explains the specialized suspension without presenting it as a replacement for this tablet strength.
The unifying principle is that each formulation has its own labeled strength, dosage form, component ratio and regulatory identity. A pharmacy product listing should preserve these distinctions rather than grouping all amoxicillin/clavulanate presentations under an interchangeable generic name.
The July 2026 FDA prescribing information includes conventional Augmentin tablets among the formulations indicated for specified infections caused by susceptible bacteria. These include certain lower respiratory tract infections, acute bacterial sinusitis, acute bacterial otitis media, skin and skin structure infections and urinary tract infections. Such indications are subject to the specific labeling, bacterial susceptibility and clinical context.
The FDA identifies conventional Augmentin tablets for adults and pediatric patients weighing 40 kg or more who are able to swallow tablets. The 250 mg/125 mg tablet should not be treated as a pediatric liquid equivalent simply because it contains 250 mg of amoxicillin. Its dosage form and clavulanate proportion remain important limitations.
A medicine's approved indication does not establish that it is the preferred antibiotic for every patient with a similarly named infection. Some illnesses are viral, and certain susceptible bacterial infections may be appropriately treated with amoxicillin alone or another narrower-spectrum option. Treatment selection depends on a clinician's assessment rather than a product-comparison table.
Augmentin is prescription-only in the United States. Patients should not select the 250/125 mg tablet based on an online strength listing, use leftover tablets from a previous illness or change the amount or frequency of a prescribed antibiotic independently. The applicable FDA label contains administration instructions, but this page does not provide individualized dosing guidance.
Readers seeking the general requirements for a clinician-issued prescription can consult the Augmentin online prescription guide. This strength-specific page focuses on identifying the prescribed product, not obtaining guaranteed treatment approval.
The 250 mg/125 mg tablet contains the same two active ingredients as other conventional Augmentin strengths and is subject to the applicable FDA-approved warnings and contraindications. The labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs, as well as previous Augmentin-associated cholestatic jaundice or hepatic dysfunction.
Commonly reported adverse reactions to the combination include diarrhea, nausea, vomiting and skin reactions. More serious risks described in the prescribing information include severe allergic reactions, serious cutaneous adverse reactions, liver injury and Clostridioides difficile-associated diarrhea. Severe breathing difficulty, facial or throat swelling or other signs of anaphylaxis require emergency medical attention.
The amount of clavulanate is important when evaluating formulation differences, but it should not be used by patients to infer a safer or better dose. The FDA's explicit warning against replacing one 500/125 mg tablet with two 250/125 mg tablets illustrates why total exposure to both active components matters.
Medication history and individual clinical circumstances can also influence prescribing. The FDA label discusses precautions and interactions involving medications such as probenecid, oral anticoagulants and allopurinol. Kidney function and allergy history require professional consideration. Patients should provide their clinician and pharmacist with a complete medication and allergy history.
Responsible antibiotic use means following the clinician's instructions, avoiding leftover-antibiotic self-treatment and not sharing prescription medicines. Augmentin does not treat viral infections such as influenza or the common cold. Readers with concerns about penicillin hypersensitivity can review the penicillin allergy guide before discussing their history with a healthcare professional.
The existence of an FDA-approved branded or generic 250 mg/125 mg tablet does not establish that a particular pharmacy currently stocks the product. Regulatory approval, product labeling, commercial distribution and local pharmacy availability are separate facts. Historical labels or catalog entries should not be interpreted as current inventory guarantees.
A pharmacy may display the Augmentin brand name while offering an independently approved generic amoxicillin/clavulanate product for dispensing where appropriate and legally permitted. Patients seeking a specific branded package should have the actual dispensed product confirmed rather than assuming that a brand-name search result represents a branded inventory item.
Out-of-pocket costs can depend on the specific product, quantity, pharmacy, insurance arrangements and applicable discounts. The presence of a generic option does not establish an identical price across manufacturers or pharmacies. Quotes should correspond to the complete 250 mg/125 mg tablet identity rather than a broader amoxicillin/clavulanate category.
The Augmentin brand price guide addresses broader branded-product costs, while the generic amoxicillin/clavulanate price guide covers generic pricing factors. This page intentionally avoids unverified offers, assumed insurance coverage or claims of guaranteed supply.
If the exact prescribed formulation is unavailable, the pharmacist should explain what legally and clinically appropriate options may exist and whether the prescriber must authorize a change. Patients should not substitute a different strength or dosage form independently.
Augmentin 250/125 mg is a conventional immediate-release prescription antibiotic tablet containing 250 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. It is a two-ingredient medicine rather than plain amoxicillin.
The first number represents 250 mg of amoxicillin, while the second represents 125 mg of clavulanic acid. These are separate active-component quantities in one tablet, producing a 2:1 amoxicillin-to-clavulanic-acid ratio.
No. Plain amoxicillin 250 mg contains amoxicillin without clavulanate. Augmentin 250/125 mg contains both amoxicillin and clavulanate potassium. These are different prescription medicines and should not be exchanged without professional assessment.
The July 2026 FDA prescribing information describes the branded product as a white, oval, film-coated tablet debossed with AUGMENTIN on one side and 250/125 on the other. Generic tablets may have different appearances and imprints.
Yes. The conventional 250/125 mg Augmentin tablet belongs to the standard immediate-release product family. It is different from Augmentin XR extended-release tablets, which have separate strengths and release characteristics.
No. The conventional tablet contains 250 mg of amoxicillin and 125 mg of clavulanic acid per tablet. The suspension contains 250 mg of amoxicillin and 62.5 mg of clavulanic acid per 5 mL after reconstitution. Their component ratios differ, and the FDA identifies no equivalent suspension strength for the 250/125 mg tablet.
No. The FDA specifically identifies these presentations as not interchangeable. Both contain 250 mg of amoxicillin, but the conventional tablet contains 125 mg of clavulanic acid while the chewable tablet contains 62.5 mg.
The ratio describes how much of each active component is present in the formulation. Products with identical amoxicillin quantities may contain different clavulanate amounts. The complete strength pair and dosage form therefore matter for product identification and professional substitution decisions.
No. Two 250/125 mg tablets would contain 500 mg of amoxicillin and 250 mg of clavulanic acid. One 500/125 mg tablet contains 500 mg of amoxicillin but only 125 mg of clavulanic acid. The FDA explicitly warns against this substitution.
No. Table 6 of the July 2026 FDA prescribing information lists no equivalent oral suspension or chewable strength for the conventional 250 mg/125 mg tablet. Formulation changes must be assessed by the appropriate healthcare professional.
An appropriately FDA-approved generic may be therapeutically equivalent to its corresponding reference product when the applicable regulatory requirements are met. The actual dosage form, strength, approval information and substitution rules must be checked. Generic packaging and tablet appearance may differ from the brand.
Yes. Approved generic products may have different colors, shapes, imprints and inactive ingredients from the branded reference product. The actual tablet should correspond to its approved product information and the medicine identified by the dispensing pharmacy.
Check the pharmacy container label for amoxicillin and clavulanate potassium, the complete 250 mg/125 mg strength pair and the conventional tablet dosage form. Ask the pharmacist to confirm the manufacturer or labeler, NDC and tablet identity when applicable.
The FDA's July 2026 labeling identifies conventional Augmentin tablets for adults and pediatric patients weighing 40 kg or more who can swallow tablets. The 250 mg/125 mg conventional tablet should not be used in pediatric patients weighing less than 40 kg. Pediatric formulation decisions require professional assessment.
No. Augmentin 250/125 mg is a prescription-only antibiotic in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. An online listing does not guarantee clinical approval or lawful prescription-free access.
No. FDA approval and published drug labeling establish regulatory product information, not real-time pharmacy inventory. A dispensing pharmacy must confirm whether the exact branded or generic strength and dosage form can actually be supplied.
No. The clavulanate component can extend activity against certain beta-lactamase-producing bacteria, but the combination is not universally preferable. Antibiotic selection depends on the suspected or confirmed infection, susceptibility and patient-specific clinical factors.
No. Leftover antibiotics should not be used for self-treatment. A new illness may be viral, may require a different medicine or may not require antibiotics at all. Unnecessary treatment can cause adverse effects and contribute to bacterial resistance.
Augmentin contains amoxicillin, a penicillin-class antibacterial. The FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. A reported penicillin allergy requires evaluation by a healthcare professional before treatment.